Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …

Currently, there is no established guidance on how to process and evaluate resected lung
cancer specimens after neoadjuvant therapy in the setting of clinical trials and clinical …

PURPOSE To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation …

Osimertinib is a third-generation, irreversible oral EGFR-tyrosine kinase inhibitor), that
potently inhibits EGFR-tyrosine kinase inhibitor-sensitizing mutations and T790M resistance …

Introduction Currently, limited data on tyrosine kinase inhibitors as neoadjuvant therapy
exist. This prospective study aimed to investigate the efficacy and safety of preoperative …

Non-small-cell lung cancer (NSCLC) represents roughly 85% of lung cancers, with an
incidence that increases yearly across the world. The introduction in clinical practice of …

Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …

Purpose The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase
inhibitor (TKI) targeted therapy for patients with EGFR-mutant non-small cell lung cancer …

Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with
the development of targeted therapies for advanced disease and concomitant molecular …